JPH10506003A - プレイオトロフィンのアンチセンスオリゴヌクレオチド - Google Patents

プレイオトロフィンのアンチセンスオリゴヌクレオチド

Info

Publication number
JPH10506003A
JPH10506003A JP8505138A JP50513896A JPH10506003A JP H10506003 A JPH10506003 A JP H10506003A JP 8505138 A JP8505138 A JP 8505138A JP 50513896 A JP50513896 A JP 50513896A JP H10506003 A JPH10506003 A JP H10506003A
Authority
JP
Japan
Prior art keywords
pleiotrophin
oligonucleotide
cells
antisense
ptn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP8505138A
Other languages
English (en)
Japanese (ja)
Inventor
ケネス ジェイ． コリー
アントン ウェルステイン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Original Assignee
Georgetown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University filed Critical Georgetown University
Publication of JPH10506003A publication Critical patent/JPH10506003A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP8505138A 1994-07-18 1995-07-18 プレイオトロフィンのアンチセンスオリゴヌクレオチド Pending JPH10506003A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27633094A 1994-07-18 1994-07-18
US08/276,330 1994-07-18
PCT/US1995/008781 WO1996002257A1 (fr) 1994-07-18 1995-07-18 Oligonucleotides antisens de pleiotrophine

Publications (1)

Publication Number Publication Date
JPH10506003A true JPH10506003A (ja) 1998-06-16

Family

ID=23056211

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8505138A Pending JPH10506003A (ja) 1994-07-18 1995-07-18 プレイオトロフィンのアンチセンスオリゴヌクレオチド

Country Status (4)

Country Link
JP (1) JPH10506003A (fr)
AU (1) AU3126595A (fr)
CA (1) CA2195450A1 (fr)
WO (1) WO1996002257A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0997150A4 (fr) 1997-03-12 2004-06-16 Takashi Muramatsu Compositions preventives et therapeutiques pour nephropathies et hepatites d'origine medicamenteuse
BR9909717A (pt) * 1998-04-17 2000-12-26 Angiogenix Inc Fatores angiogênicos terapêuticos e métodos para seu uso
KR100608276B1 (ko) 1998-08-24 2006-08-02 무라마쯔 다카시 동맥경화 및 ｐｔｃａ술후의 혈관 재협착에 대한예방·치료제
JP2002526777A (ja) * 1998-10-06 2002-08-20 ジョージタウン ユニバーシティ プレイオトロフィン検出法
US7141384B1 (en) 1998-10-06 2006-11-28 Georgetown University Detection of pleiotrophin
US6709855B1 (en) 1998-12-18 2004-03-23 Scios, Inc. Methods for detection and use of differentially expressed genes in disease states
WO2000035473A2 (fr) * 1998-12-18 2000-06-22 Scios Inc. Methodes de detection et d'utilisation de genes exprimes de façon differentielle dans des maladies
US6770264B2 (en) 2001-11-13 2004-08-03 Noville, Inc. Chewing gum compositions comprising diglycerol
CN100386435C (zh) * 2005-12-19 2008-05-07 中国人民解放军军事医学科学院放射与辐射医学研究所 抑制多效生长因子基因表达的小干扰rna及其应用

Also Published As

Publication number Publication date
AU3126595A (en) 1996-02-16
WO1996002257A1 (fr) 1996-02-01
CA2195450A1 (fr) 1996-02-01

Similar Documents

Publication Publication Date Title
US8647820B2 (en) Circular dumbbell decoy oligodeoxynucleotides (CDODN) containing DNA bindings sites of transcription
EP0703979B1 (fr) Methode de traitement du sarcome de kaposi par des oligonucleides antisens
EP1352061B9 (fr) Procede pour inhiber l'expression d'un gene cible
EP0732929B1 (fr) Utilisation therapeutique de leurres d'elements cis in vivo
IL194419A (en) Dsrna to inhibit the expression of a 5eg gene in a human cell, a pharmaceutical compound containing it, a vector method
US20030144240A1 (en) Antisense strategy to modulate estrogen receptor response (ER alpha and/or ER beta)
WO2010006239A2 (fr) Régulation d'apoptose par variants d'épissure spécifique neurale d'ig20
JP2002529066A (ja) 結合組織成長因子（ｃｔｇｆ）および使用方法
WO2006012625A2 (fr) Oligonucleotides leurres stat3 et leurs utilisations
KR20010042848A (ko) 인슐린유사 성장인자 ⅱ의 안티센스 올리고뉴클레오타이드서열 및 이를 이용한 세포성장 조절방법
JPH10506003A (ja) プレイオトロフィンのアンチセンスオリゴヌクレオチド
CN108251420A (zh) 抑制人和动物中CTGF基因表达的siRNA、包含其的组合物及其应用
JP4228111B2 (ja) 動脈硬化およびｐｔｃａ術後の血管再狭窄に対する予防・治療剤
US6034234A (en) Double-stranded oligonucleotide and anticancer agent containing the same as active ingredient
WO1993003770A1 (fr) Procede et compositions utilises pour la reprogrammation cellulaire
US20040220131A1 (en) Method for treatment of cancerous angiogenic disorders
WO2004092379A9 (fr) Methode de traitement de troubles angiogeniques
EP1071764B1 (fr) Oligonucleotides antisens destines a inhiber l'expression d'une sous-unite de l'integrine alphav
CN117210468B (zh) 靶向调控PCSK9基因表达的siRNA及其应用
WO1998049287A2 (fr) Oligonucleotides antisens specifiques d'une thymidylate synthase
CN108251421A (zh) 抑制人和动物中COL1A1基因表达的siRNA、包含其的组合物及其应用
CA2446810A1 (fr) Oligonucleotides antisens du recepteur du facteur de croissance epidermique
WO1999027087A1 (fr) Oligonucleotides anti-sens specifiques de la cdk4
JP4316661B2 (ja) 転写ｄｎａ結合部位を含む環状ダンベルデコイオリゴデオキシヌクレオチド（ｃｄｏｄｎ）
CN114958839A (zh) 抑制肌肉瘤细胞中FOXO1基因表达的siRNA序列及应用